CAPTURE: Circulating tumour DNA assessment of PIK3CA to guide treatment response

许多乳腺癌会将少量的DNA（称为循环肿瘤DNA或ctDNA）释放到患者的血液中。该提案是一项临床试验，将检查使用ctDNA来跟踪血液中特定治疗靶点（PIK3CA基因突变）的水平，以便及时引入靶向治疗（PI3K抑制剂）。该试验旨在改善雌激素受体阳性转移性乳腺癌患者的预后。

Many breast cancers shed small amounts of DNA (called circulating tumor DNA or ctDNA) into the patient’s bloodstream. This proposal is for a clinical trial which will examine the use of ctDNA to follow levels of a specific therapeutic target (a mutation in a gene called PIK3CA) in blood, to allow the timely introduction of a targeted therapy (PI3K inhibitor). The trial aims to lead to improved outcomes for women with estrogen receptor positive metastatic breast cancer.